Artiva Biotherapeutics awarded Chief Tech Operations Officer Horan Christopher 40,000 shares at $0 per share and 120,000 derivative securities on September 9, 2026. The awards left him with 323,084 shares and 120,000 derivative securities, representing about 12.4% and 100.0% of those respective holdings.
Key Highlights
- Horan Christopher’s resulting common-share holding was 323,084 shares.
- The executive received 120,000 derivative securities in a separate award.
- The 40,000-share transaction represented about 12.4% of his resulting share holding.
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) awarded Chief Tech Operations Officer Horan Christopher 40,000 shares at $0 per share on September 9, 2026.
Award Includes Shares and Derivative Securities
Horan Christopher also received 120,000 derivative securities on September 9, 2026. That award was recorded under the same transaction code A. His resulting derivative-securities holding was 120,000. The stock award left him with 323,084 shares. Artiva Biotherapeutics identifies Christopher as its Chief Tech Operations Officer. The share award carried a price of $0 per share.
Awards Measured Against Resulting Holdings
The 40,000 shares represented about 12.4% of Christopher’s resulting holding of 323,084 shares. The 120,000 derivative securities represented about 100.0% of his resulting derivative-securities holding of 120,000. The percentages apply to different holdings. One measures the common-share award against shares held after the transaction, while the other measures the derivative-securities award against derivative securities held afterward. Transaction code A denotes an award, grant, or other Acquisition from the company.
FAQs
Q: What shares did Artiva Biotherapeutics award Horan Christopher?
A: Artiva Biotherapeutics awarded Chief Tech Operations Officer Horan Christopher 40,000 shares at $0 per share on September 9, 2026. The transaction used code A.
Q: How many shares did Horan Christopher own after the ARTV award?
A: Horan Christopher’s resulting Artiva Biotherapeutics share holding was 323,084 shares. The 40,000-share award represented about 12.4% of that resulting holding.
Q: Did Horan Christopher receive derivative securities?
A: Yes. Horan Christopher received 120,000 derivative securities, leaving him with 120,000 derivative securities and making the award about 100.0% of that resulting holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.